Histopathological Changes in Some Organs of Diabetic Rats Administered Aqueous or Ethanolic Root Extract of Uvaria Chamae

F. E. Olumesi¹, I. O. Onaogbe¹, G. E. Ezé¹, S. F. Omoruyi², ¹University of Benin, Benin City, Nigeria, Benin, Nigeria, ²Texas A & M, Corpus Christi, TX

Background: Uvaria chamae is a medicinal plant that is used in many parts of the world in the treatment of diabetes, and other diseases. The chemical constituents of Uvaria chamae, include C-benzylated monoterpens, aromatic oils, flavanones, C-benzylated flavanones, and C-benzylated dihydrochalcones. Traditionally, the root extracts are used in the treatment of many diseases, including diabetes. However, the use of this plant extracts in the treatment of diabetes have not been scientifically validated. In this study, we evaluated the histopathological changes in the heart, liver and pancreas of normal and diabetic rats administered aqueous or ethanolic extract of Uvaria chamae roots. Methods: Thirty six Sprague Dawley rats were assigned by weight into six groups [6 rats per group, average body weight 265.23 ± 7.20 g] as follows: Healthy rats receiving de-ionized water (Normal Control); Normal rats receiving aqueous extract (Normal plus Aqueous Extract); Normal receiving ethanolic extract (Normal plus Ethanolic Extract); Diabetic rats receiving de-ionized water (Diabetic Control); Diabetic rats receiving aqueous extract (Diabetic plus Aqueous Extract); and Diabetic rats receiving ethanolic extract (Diabetic plus Ethanolic Extract). Diabetes was induced using a single injection of streptozotocin (Sigma-Aldrich, 60 mg/kg body weight in 0.05 M-citrate buffer, pH 4.5) intraperitoneally. Normal and diabetic rats were then administered the aqueous or ethanolic extract (300 mg/kg body weight per day) for 35 days. Animals were euthanized by decapitation and blood collected for glucose assay. Organs were collected and preserved in buffered formalin for histopathological evaluation. Results: There was a significant (p<0.05) decrease in blood glucose levels in the diabetic groups treated with aqueous or ethanolic extract compared to the diabetic control. We observed intimal ulceration, medial thickening and luminal stenosis of the coronary artery in the heart of diabetic control rats compared to the normal control. Diabetic rats treated with ethanolic extract showed good luminal patency. We also observed mild vascular congestion and dilatation in the diabetic rats treated with the aqueous extract with well delineated luminal patency. The liver of the diabetic control group showed portal congestion and infiltrates of chronic inflammatory cells(portal hepatitis) when compared to the normal control. However, treatment of the diabetic groups with aqueous or ethanolic extract showed dilatation of blood vessels and activation of the kupffer cells (local immune system) when compared to the diabetic control. The normal control groups treated with aqueous or ethanolic extract showed exuberant pancreatic islet cells compared to the untreated normal control. Similarly, the diabetic groups treated with aqueous or ethanolic extract showed resurgent pancreatic islet cells compared to the diabetic control group. Conclusion: The observed activation of hepatic kupffer cells and the resurgence of pancreatic islet cells due to aqueous or ethanolic extract consumption are indicative of the potential benefits of each extract in the effective management of diabetes. The observed good luminal patency of the coronary artery by either extract supplementation may prevent lipid deposition in the arteries that is often associated with the development of diabetic complications.

Anti-diabetic properties of combined inositol hexakisphosphate and inositol in streptozotocin-induced type 2 diabetes mellitus Sprague-Dawley rats

S. R. Foster¹, R. L. Alexander Lindo¹, L. L. Dilworth¹, J. Bustamante², F. O. Omoruyi³, ¹The University of the West Indies, Mona Campus, Kingston, Jamaica, ²Texas A&M University, Kingsville, TX, ³Texas A&M University, Corpus Christi, TX

Background: Diabetes mellitus is ranked among the major causes of morbidity and mortality associated with non-communicable diseases worldwide. Type 2 diabetic patients struggle with classic early symptoms of increased body weight, dyslipidemia, polyphagia, polydipsia and polyuria. Inositol hexakisphosphate (IP6) is a plant constituent found in appreciable quantities especially in grains and seeds while inositol is a carbohydrate found in plants and animals. Inositol and IP6 are thought to individually exhibit hypoglycemic activities but the full mechanism is not yet known. Therefore the anti-diabetic effects of an IP6 and inositol combination in a type 2 diabetes mellitus (T2DM) rat model was evaluated in this study. Methods: Thirty male Sprague-Dawley rats with average body weight of 168 ± 5.9 g were used in this 8 week study. Type 2 diabetes mellitus was induced in 18 of these rats by feeding them high-fat diet for 4 weeks followed by intravenous administration of a low dose of streptozotocin (Sigma-Aldrich, 35 mg/kg body weight) in 0.1 M-citrate buffer, pH 4.5) after two weeks. Type 2 diabetes mellitus was confirmed by hyperglycemia (blood glucose ≥ 300 mg/dL) and a positive response to an anti-diabetic drug response test. Diabetic rats were placed into three groups (6 rats per group) namely; IP6 and inositol combination (IP6+INO; 650 mg/kg body weight/day), glibenclamide (Glb; 10 mg/kg body weight/day) and diabetic control (DC). In addition, two groups of non-diabetic control rats were fed normal diet (NC) and high fat diet (HFC) during the initial 4 weeks of the experiment. However, for the final four weeks, all rats were fed normal diet and given their respective treatment regimes. The rats were fasted overnight, euthanized by decapitation and blood samples were collected at the end of the 8 week period. Results: Treatment with IP6 & inositol combination significantly reduced blood glucose concentration (306 ± 53 mg/dL) and insulin resistance score (1.93 ± 0.45) compared to the diabetic control group (522 ± 24 mg/dL and 5.10 ± 0.69 respectively; p < 0.05). A similar effect was observed with Glibencamide. However, the combined supplement was more effective in lowering serum total cholesterol and triglycerides by 26% and 31% respectively compared to the glibenclamide treated group (p < 0.05). Body weight, fluid intake and food consumption were also significantly reduced in the IP6+INO group by 8%, 16% and 10% respectively compared to the Glibenclamide treated group (p < 0.05). Administration of the combined supplement increased glucose uptake was reduced by 52% and 28% respectively, whereas serum leptin concentration was increased by 34% in rats treated with the combined supplement compared to the diabetic control group (p < 0.05). Conclusion: Treatment of T2DM rats with IP6 and inositol combination significantly improved blood glucose concentration and ameliorated insulin resistance, dyslipidemia, polyphagia and polydipsia. This study shows that a combined IP6 and inositol supplementation may be effective in the management of T2DM and associated metabolic disorders.
count (PLT), and 168 hours for all flow cytometry parameters assessed. SD rat blood was stable up to 28 hours for CBC, 32 hours for RETIC, 72 hours for Auto DIFF and WBC, and 54 hours for all flow cytometry parameters. Lymphocyte subsets were stable in Wistar rat blood for 30 hours. CD-1 and C57BL/6 mouse blood was stable for 96 and 72 hours, respectively, for lymphocyte subsets.

**Conclusion:** All outlined criteria for the validation of extended sample stability in NHP, canine, rat and mouse whole blood samples for hematology as well flow cytometry parameters were met and have been used to support discovery and multispecies pre-clinical studies. Therefore, with the evaluation of extended sample stability we have been able to provide support across multiple sites, and offer a more robust methodology and confidence in reported results of whole blood samples.

**Evaluation of the Meso Scale Discovery Rat Skeletal Troponin I Assay in Rat and Mouse**

T. Lambert, K. Lynch, N. Chau, T. Sellers. *GlaxoSmithKline, King of Prussia, PA*

Skeletal troponin I (sTnI) is a member of the troponin complex of regulatory proteins required for muscle contraction. Recent evidence suggests that skeletal muscle injury results in leakage of sTnI into blood and measurement of serum or plasma levels of sTnI may provide a noninvasive biomarker of muscle injury. Our objective was to evaluate the Meso Scale Discovery® (MSD) Rat Skeletal Troponin I Assay for measurement of skeletal troponin I in rat serum. Acceptable precision (CV ≤10%) and accuracy (RE ±13%) of standard curve values were observed across 10 analytical runs. Precision of sTnI values in rat serum samples was excellent (CVs ≤10%) at concentrations in the range of 5-150µg/L; less precision was observed (CV=21%) in the area of the LLOQ (0.27µg/L). Dilutional linearity (y=1114.8x – 4782.2; r²=0.99) and recovery (101-106%) of sTnI in rat serum was demonstrated. Serum sTnI was stable for up to 6 months at -80°C. Serum sTnI values in clinically healthy Wistar rats (n=20/sex) were below LLOQ to 11.4µg/L for males and at or below LLOQ for females. In two nonclinical safety studies, sTnI increases (up to 1984µg/L) correlated with histologic evidence of myofiber degeneration and/or necrosis and increases in AST and aldolase. In mice, sTnI increases (474 to 1859µg/L) were observed in plasma of muscular dystrophy mutant mice (C57BL/10ScSn-mdx/J) compared to wild-type C57BL mice (0.38-3.09µg/L). In conclusion, the MSD rat skeletal troponin I assay performed well and sTnI increases correlated with skeletal muscle injury in rats and mice.